Press Releases from curasan AG (20 total)
curasan AG: Dental Business Unit acquired as of June 1
Kleinostheim, Germany, June 6, 2013 – curasan AG, Germany, has acquired a large part of the “Oral Regenerative Medicine” division of Riemser Pharma GmbH, Germany, effective June 1, 2013.
curasan AG now owns the marketing and distribution rights for the products covered by the contract and is assuming the sales structures, including the na-tional and international customer base.
As a result of this change, curasan has immediate access to the dental market…
curasan AG now sells bone regeneration material in injectable form
Kleinostheim, 05.12.2012 – curasan AG, listed on the General Standard (ISIN: DE 000 549 453 8), has introduced its new bone regeneration material CERASORB® Ortho Paste to the German and European markets at the beginning of December.
CERASORB® Ortho Paste is comprised of fine granules of the proven, fully resorbable, synthetic material CERASORB® M Ortho suspended in a hyaluronic acid hydrogel-matrix. The paste-like product has the advantage that it is…
curasan AG commences operations in the European market with the appointment of a …
Kleinostheim, 15.02.2012 – curasan AG, listed in the General Standard (ISIN: DE 000 549 453 8), created a new post on 1st February 2012 in relation to the active expansion of its European sales network in the fields of Orthopaedics and trauma surgery. Mr. Lee McCann BSc Business Administration (North West University of Applied Science, London, U.K.), will be operating as the organisation’s International Sales Director for Orthobiologics with immediate…
curasan AG: Novel bone regeneration material approved for sale in Europe
Kleinostheim, Germany – curasan AG, which is listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has received European approval for a novel synthetic bone regeneration material.
Osseolive® is a bioactive, poly-crystalline calcium-alkali-phosphate ceramic, which has a stimulating effect on bone formation as well as on bone mineralisation.
“With Osseolive® emerging from our well-stocked development pipeline, we now have an ideal extension to our tricalcium-phosphate…
curasan AG receives license for Osbone® Dental in the USA
Kleinostheim, Germany, 10th February 2011 - curasan AG, which is listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has received FDA certification and, therefore, marketing authorization throughout the USA of the synthetic bone replacement material Osbone® Dental which already has been authorized in the EU as Osbone®.
Osbone® Dental is suitable for utilisation in general bone surgery, particularly in implantology and oral…
curasan AG signs sales agreement with Stryker S.A.
Kleinostheim, Germany, 9 February 2011 – curasan AG, listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has signed an agreement with Stryker S.A., Montreux, Switzerland, to sell and market bone replacement and regeneration materials for different orthopedic indications.
Starting summer 2011, Stryker anticipates launching the products in selected European countries to be potentially followed by further target markets.
"Partnering with Stryker, a powerful global…
curasan AG receives approval for Cerasorb® M ORTHO in Canada
Kleinostheim, Germany – curasan AG, listed in the General Standard (ISIN: DE 000 549 453 8) has received the certification for the synthetic bone regeneration material Cerasorb® M ORTHO from the Canadian authorities, Health Canada.
“This news has come as a pleasant surprise”, stated Hans Dieter Rössler, CEO. “Since the approval process for medical devices by the Canadian authorities is highly demanding, we were actually expecting the certification some time…
curasan AG: Bioactive bone regeneration material approved for sale in Europe
Kleinostheim, Germany – curasan AG, listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8) has received European approval for its new granular bone regeneration material Ceracell®.
Hans Dieter Rössler, CEO of curasan AG, considers the CE-certification of Ceracell® to be another milestone in the implementation of the product offensive launched at the beginning of the year: “We are implementing our strategy of offering innovative…
curasan AG: Profits warning for 2010
Kleinostheim, Germany – curasan AG, listed in the General Standard (ISIN: DE 000 549 453 8) expects to make a considerable profit instead of the two million euro loss announced for the financial year 2010.
The reason for this is the contract agreement that has just been concluded for the sale of the oncological product Mitem® to the Speciality European Pharma Ltd. (SEP), London, and the extraordinary earnings associated with…
curasan AG scouts for sales partners for ATR®
Supporting wound healing and tissue regeneration through the extraction of autologous platelet-mediator-concentrate (PMC) – high patient compatibility using autologous blood – No need for centrifuges and external laboratories
Kleinostheim, Germany – curasan AG, listed in the General Standard of the Frankfurt Stock Exchange (ISIN: DE 000 549 453 8), has commenced with the pre-marketing activities for the launch of its new product ATR® (Advanced Tissue Regeneration).
ATR® is a standardised system…
curasan AG: cooperation agreement for new product line
Kleinostheim, Germany, 25th May 2010 – curasan AG, listed in the General Standard of the Frankfurt Stock Exchange (ISIN: DE 000 549 453 8), has concluded a contract with Matricel GmbH, Herzogenrath, which secures exclusive rights for both companies over a jointly developed new product line. As manufacturer, Matricel GmbH will supply curasan AG, which in turn holds the marketing rights.
In contrast to the bone augmentation material Cerasorb®, which is…
curasan AG: 2009 fiscal year above expectations
Kleinostheim, Germany, 6th May 2010 – curasan AG, listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), was able to achieve an annual surplus of 0.2 million Euro in the fiscal year 2009. The performance per share amounted to 0.03 Euro.
“We had originally expected a slight negative performance for 2009 due to the product offensive introduced in autumn. Therefore, it is all the…
curasan AG: One million units of Cerasorb® produced
Kleinostheim, Germany, 28th April 2010 – The employees of curasan AG awaited the recently produced batch of Cerasorb® M with particular excitement – because amongst this batch was the one millionth bottle ready for sale. Depending on requirements, the bottles contain between 0.5 and 30 grams of the synthetic bone substitute material. The batch was part of a production order placed by Riemser Arzneimittel AG, which has been selling Cerasorb®…
curasan AG launches bone substitute Osbone® – the synthetic alternative witho …
Frankfurt/Kleinostheim, Germany, 16th March 2010 – In Germany alone, every year about 800,000 tooth implants are placed. In the case of almost every second patient bone augmentation is necessary, because the jawbone atrophy is already too advanced. The development of bone substitute materials has advanced considerably over the last few years, particularly in the area of scaffold substances. There is a broad spectrum ranging from autologous, fully synthetic to xenogenic…
curasan AG: New US subsidiary for orthopaedics
Kleinostheim, Germany, 18th February 2010 – curasan AG, listed in the General Standard of the Deutsche Börse AG (ISIN: DE 000 549 453 8), is commencing the sale, through a subsidiary, of its synthetic bone regeneration material Cerasorb® M Ortho in the United States.
The newly founded curasan Inc., with its headquarters in Massachusetts, is responsible for commercial and logistical management as well as marketing activities. This occurs in coordination with…
Curavisc®: successful study regarding the treatment of chronic facet syndrome
A new study was presented at the 4th Annual Congress of the German Spine Society in Munich – it demonstrated the long-term effect of Curavisc® in the treatment of chronic facet syndrome
Kleinostheim, Germany – It has now been proven that the use of curasan AG’s hyaluronic acid preparation Curavisc® is safe and sustainably effective also for the treatment of chronic facet syndrome.
Facet syndrome is a chronic pain syndrome caused by…
curasan AG signs a research agreement with Ben-Gurion University
Kleinostheim, Germany, 17th November 2009 – curasan AG, which is listed on the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has signed a research and development agreement with the Ben-Gurion University of the Negev (BGU), Israel.
The cooperation project on which the agreement focuses is funded by the German Federal Ministry of Education and Research (BMBF) and has the ultimate goal of developing special carrier…
curasan AG received licence for ATR®
Kleinostheim, Germany, 16 October 2009 – curasan AG, which is listed on the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has been received CE certification and, therefore, marketing authorization for the ATR® (Advanced Tissue Regeneration) product.
ATR® is a disposable system that is used to enrich the body’s own growth factors to a level many times higher than normal blood values. The most important areas…
Curavisc® after knee arthroscopy examined in clinical trial: significant reduct …
A Curavisc® trial was presented at the 58th Annual Conference of the North German Association of Orthopaedic Surgeons – proof of the safer, more effective use of a hyaluronic acid preparation from curasan AG – Curavisc® is recommended for routine clinical use
Kleinostheim – A presentation on the high level of effectiveness and safety of the Curavisc® hyaluronic acid preparation from curasan AG in post-operative knee arthroscopy treatment was given at…
Cerasorb® M used successfully during acetabular cup replacement
curasan AG presented innovative medical products from the Cerasorb® umbrella brand at the 57th annual congress of the Association of South-German Orthopaedic Surgeons (Vereinigung Süddeutscher Orthopäden e. V.) – Report on experiences with the use of Cerasorb® M during revision operations to correct acetabular cup loosening in the hip joint: use of Cerasorb® M for filling of defects successful in 30 older patients – Low risk of infection documented …
